USANA Health Sciences Future Growth

Future criteria checks 3/6

USANA Health Sciences is forecast to grow earnings and revenue by 45.7% and 0.1% per annum respectively. EPS is expected to grow by 46.2% per annum. Return on equity is forecast to be 7% in 3 years.

Key information

45.7%

Earnings growth rate

46.23%

EPS growth rate

Personal Products earnings growth	32.0%
Revenue growth rate	0.1%
Future return on equity	6.98%
Analyst coverage	Low
Last updated	24 Oct 2025

Recent future growth updates

Recent updates

USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

Oct 16

USANA Q3 2025 Preview: Short-Term Challenges Amid Strategic Transition

Oct 13

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

Oct 11

USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive But Perhaps Not Attractive Enough

Jul 18

Shareholders May Be Wary Of Increasing USANA Health Sciences, Inc.'s (NYSE:USNA) CEO Compensation Package

May 12

The Market Doesn't Like What It Sees From USANA Health Sciences, Inc.'s (NYSE:USNA) Earnings Yet As Shares Tumble 25%

Apr 08

There Are Reasons To Feel Uneasy About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Apr 04

Should You Think About Buying USANA Health Sciences, Inc. (NYSE:USNA) Now?

Dec 09

USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital

Sep 26

India Expansion And Decisive Acquisitions Promise Growth Amid Analyst Concerns Over Shrinking Margins

Sep 24 Expansion into India and strategic acquisitions offer significant growth opportunities for USANA, potentially boosting revenue and diversifying its market presence.

Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?

Sep 08

USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jul 26

There Is A Reason USANA Health Sciences, Inc.'s (NYSE:USNA) Price Is Undemanding

Jul 17

USANA Health Sciences (NYSE:USNA) Might Be Having Difficulty Using Its Capital Effectively

May 29

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 03

Here's What's Concerning About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Jul 27

Earnings and Revenue Growth Forecasts

NYSE:USNA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	922	41	64	N/A	1
12/31/2026	903	30	53	N/A	1
12/31/2025	920	15	29	N/A	1
9/27/2025	913	17	N/A	N/A	N/A
6/28/2025	899	34	51	63	N/A
3/29/2025	876	35	49	59	N/A
12/28/2024	855	42	51	61	N/A
9/28/2024	862	54	66	81	N/A
6/29/2024	875	55	59	74	N/A
3/30/2024	900	62	60	75	N/A
12/30/2023	921	64	56	71	N/A
9/30/2023	928	60	75	85	N/A
7/1/2023	948	63	79	92	N/A
4/1/2023	974	65	86	97	N/A
12/31/2022	999	69	94	104	N/A
10/1/2022	1,038	77	78	88	N/A
7/2/2022	1,079	89	84	97	N/A
4/2/2022	1,151	108	108	121	N/A
1/1/2022	1,186	117	108	121	N/A
10/2/2021	1,230	136	133	144	N/A
7/3/2021	1,254	139	148	156	N/A
4/3/2021	1,176	129	140	149	N/A
1/2/2021	1,135	125	145	160	N/A
9/26/2020	1,095	116	149	168	N/A
6/27/2020	1,058	110	149	169	N/A
3/28/2020	1,055	103	131	152	N/A
12/28/2019	1,061	101	110	127	N/A
9/28/2019	1,089	102	97	111	N/A
6/29/2019	1,125	109	N/A	116	N/A
3/30/2019	1,170	121	N/A	138	N/A
12/29/2018	1,189	126	N/A	152	N/A
9/29/2018	1,163	88	N/A	167	N/A
6/30/2018	1,128	81	N/A	125	N/A
3/31/2018	1,084	70	N/A	141	N/A
12/30/2017	1,047	63	N/A	124	N/A
9/30/2017	1,027	90	N/A	124	N/A
7/1/2017	1,020	97	N/A	145	N/A
4/1/2017	1,021	99	N/A	125	N/A
12/31/2016	1,006	100	N/A	137	N/A
10/1/2016	986	102	N/A	119	N/A
7/2/2016	965	98	N/A	113	N/A
4/2/2016	940	97	N/A	101	N/A
1/2/2016	918	95	N/A	111	N/A
10/3/2015	914	92	N/A	112	N/A
7/4/2015	872	86	N/A	120	N/A
4/4/2015	827	80	N/A	126	N/A
1/3/2015	790	77	N/A	105	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: USNA's forecast earnings growth (45.7% per year) is above the savings rate (3.1%).

Earnings vs Market: USNA's earnings (45.7% per year) are forecast to grow faster than the US market (15.5% per year).

High Growth Earnings: USNA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: USNA's revenue (0.1% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: USNA's revenue (0.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: USNA's Return on Equity is forecast to be low in 3 years time (7%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/27 04:07
End of Day Share Price	2025/10/24 00:00
Earnings	2025/09/27
Annual Earnings	2024/12/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

USANA Health Sciences, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Scott Van Winkle	Canaccord Genuity
John San Marco	Janney Montgomery Scott LLC
Stephanie Schiller Wissink	Jefferies LLC

USANA Health Sciences Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year 2025

Consensus EPS estimates fall by 53%

Price target decreased by 40% to US$39.00

USANA Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for Fiscal Year 2025

Price target increased by 26% to US$65.00

Consensus EPS estimates fall by 26%

Recent updates

Third quarter 2025 earnings: Revenues and EPS in line with analyst expectations

USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year 2025

USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

USANA's Vitamin D Supplement Shines Bright with ConsumerLab.com Seal of Approval--Setting the Standard for Product Quality

USANA Q3 2025 Preview: Short-Term Challenges Amid Strategic Transition

Consensus EPS estimates fall by 53%

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

Price target decreased by 40% to US$39.00

Investor sentiment deteriorates as stock falls 25%

USANA Health Sciences, Inc. to Report Q3, 2025 Results on Oct 21, 2025

USANA Launches Next-Generation Celavive Skincare: Advanced Formulas, Expert Ambassadors, Proven Results

USANA Expands Its Nutritionals Line with Powerful New Products and Enhanced Formulas

Chief People Officer notifies of intention to sell stock

USANA Introduces New and Upgraded Products, Along with Its Health Professional Advisory Council

Insufficient new directors

Chief Sales Officer recently sold US$106k worth of stock

Chief Sales Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 17%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

USANA Health Sciences, Inc. (NYSE:USNA) Looks Inexpensive But Perhaps Not Attractive Enough

USANA Health Sciences, Inc. to Report Q2, 2025 Results on Jul 22, 2025

Chief Operating Officer recently sold US$191k worth of stock

Chief Operating Officer notifies of intention to sell stock

Chief Financial Officer recently sold US$135k worth of stock

Shareholders May Be Wary Of Increasing USANA Health Sciences, Inc.'s (NYSE:USNA) CEO Compensation Package

Investor sentiment improves as stock rises 15%

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

USANA Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for Fiscal Year 2025

USANA Health Sciences, Inc Clinical Study Shows Usana Celavive's Resurfacing Serum to Improve Appearance of Skin in Just Two Weeks

USANA Health Sciences, Inc., Annual General Meeting, May 19, 2025

USANA Health Sciences, Inc. to Report Q1, 2025 Results on Apr 22, 2025

Price target increased by 26% to US$65.00

The Market Doesn't Like What It Sees From USANA Health Sciences, Inc.'s (NYSE:USNA) Earnings Yet As Shares Tumble 25%

There Are Reasons To Feel Uneasy About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Investor sentiment deteriorates as stock falls 16%

Insider recently sold US$147k worth of stock

Consensus EPS estimates fall by 26%

Full year 2024 earnings: EPS misses analyst expectations

USANA Health Sciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2025

Chief Financial Officer exercised options and sold US$103k worth of stock

USANA Health Sciences, Inc. Appoints Kathryn Armstrong as New Chief Scientific Officer

Price target increased by 7.5% to US$50.00

USANA Health Sciences, Inc. (NYSE:USNA) acquired 78.85% stake in Hiya Health Products LLC for approximately $260 million.

Should You Think About Buying USANA Health Sciences, Inc. (NYSE:USNA) Now?

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

USANA Health Sciences, Inc. Updates Consolidated Earnings Guidance for the Fiscal Year 2024

USANA Health Sciences, Inc. to Report Q3, 2024 Results on Oct 22, 2024

USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital

India Expansion And Decisive Acquisitions Promise Growth Amid Analyst Concerns Over Shrinking Margins

Is There Now An Opportunity In USANA Health Sciences, Inc. (NYSE:USNA)?

USANA Health Sciences, Inc. Launches New, Innovative Skincare and Protein Products Resurfacing Serum and Whey Protein Isolate Up the Game for USANA

Chief People Officer recently sold US$240k worth of stock

Consensus EPS estimates fall by 10%

USANA Health Sciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Revenue and earnings growth

Price target decreased by 8.0% to US$52.00

There Is A Reason USANA Health Sciences, Inc.'s (NYSE:USNA) Price Is Undemanding

USANA Health Sciences, Inc. to Report Q2, 2024 Results on Jul 23, 2024

Founder & Chairman Emeritus recently sold US$180k worth of stock

Founder & Chairman Emeritus notifies of intention to sell stock

USANA Health Sciences (NYSE:USNA) Might Be Having Difficulty Using Its Capital Effectively

Chief People Officer recently sold US$132k worth of stock

Now 22% undervalued

Chief Financial Officer recently sold US$233k worth of stock

Insider notifies of intention to sell stock

Insider recently sold US$179k worth of stock

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

First quarter 2024 earnings: EPS exceeds analyst expectations

Is Now The Time To Look At Buying USANA Health Sciences, Inc. (NYSE:USNA)?